Director/PDMR Shareholding

Home | Investors | RNS | Director/PDMR Shareholding
RNS Number : 1866N
Novacyt S.A.
18 May 2020
 

Novacyt S.A.

 

(“Novacyt” or the “Company”)

 

Director/PDMR Shareholdings

 

Paris, France and Camberley, UK – 18 May 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 15 May 2020, the following Directors purchased ordinary shares of €1/15 each in the Company (the “Ordinary Shares”):

 

Director

Title

Number of Ordinary Shares purchased

Price paid per Ordinary Share

Resultant beneficial holding

% of issued share capital

Graham Mullis

 

Chief Executive Officer

 

9,493

 

 

310p

 

61,631

 

 

0.09%

James Wakefield

Non-Executive Director & Chairman

 

20,000

 

 

304.9p

 

36,839

 

0.05%

 

  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 

Graham Mullis, Chief Executive Officer

 

2.

Reason for the Notification

a)

Position/status

See 1(a) – classified as a PDMR of the Company

 

b)

Initial notification/ Amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Novacyt S.A.

b)

LEI

213800BWAC2BF295EG28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of €1/15 each

 

Identification code

FR0010397232

b)

Nature of the transaction

Acquisition of Ordinary Shares

 

c)

Price(s) and volume(s)

 

Price

Volume

310 pence

9,493

d)

Aggregated information:

· Aggregated volume

· Price

 

N/A Single transaction as above

Price

Volume

310 pence

9,493

 

 

e)

Date of the transaction

 

15 May 2020

f)

Place of the transaction

AIM

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

 

James Wakefield, Non-Executive Director & Chairman of the Board

 

2.

Reason for the Notification

a)

Position/status

See 1(a) – classified as PDMRs of the Company

 

b)

Initial notification/ Amendment

Initial Notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Novacyt S.A.

b)

LEI

213800BWAC2BF295EG28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of €1/15 each

 

Identification code

FR0010397232

b)

Nature of the transaction

Acquisition of Ordinary Shares

 

c)

Price(s) and volume(s)

 

Price

Volume

a) 304.9 pence

20,000

d)

Aggregated information:

· Aggregated volume

· Price

 

N/A single transaction as above

Price

Volume

a) 304.9p

20,000

 

 

e)

Date of the transaction

 

15 May 2020

f)

Place of the transaction

AIM

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

– End –

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

[email protected] / [email protected] 

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

[email protected] 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 

END

 
 

DSHGPUAAAUPUUMR

Download as a PDF
Return to RNS Feed